X

Get our occasional Market Report emails

sent straight to your inbox

There’s no charge for this.

Getting latest data loading
X

Request a Call to Trade

In addition to the daily Research emails, I would also like to receive the Accendo Markets Weekly Newsletter and occasional Market Report emails highlighting various trading opportunities.
When you enter your telephone number, we may call or message you occasionally with trading opportunities. You can opt out at any time
Home / Momentum / AstraZeneca PLC (AZN.L) 05-05-20

This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.

AstraZeneca PLC (AZN.L) 05-05-20

Will AstraZeneca PLC (AZN.L) continue this relentless rise, setting new highs?

  • Currently trading at 8429p (at time of writing), performance has been exceptional of late.
  • Will it hit resistance, or is the trend your friend?
  • Is this one for momentum traders?
  • The price has been moving upwards, however, past performance is not necessarily an indication of the future.
  • Technical traders should be mindful of breaking news and events. This can influence price trends. Check our website and news outlets for updates.
  • Shares -0% from 12-month highs; +48% from 12 month lows.

Latest News

01 May:  DZ Bank reiterates its sell rating on AstraZeneca (AZN) and increased the target price to 7300p (from 6500p).

01 May:  JP Morgan Cazenove reiterates its overweight rating on AstraZeneca (AZN) and increased the target price to 9500p (from 8500p).

01 May:  Barclays Capital reiterates its overweight rating on AstraZeneca (AZN) and increased the target price to 9200p (from 9000p).

30 Apr:  Credit Suisse reiterates its outperform rating on AstraZeneca (AZN) and increased the target price to 9000p (from 8500p).

30 Apr:  HSBC reiterates its reduce rating on AstraZeneca (AZN) and increased the target price to 6690p (from 6450p).

29 Apr:  AstraZeneca posted an increase in Q1 revenues, lifted by sales of new medicines. It also announced that it was testing drugs to fight the coronovirus.

Source: Bloomberg, Reuters, Alpha Terminal, FT, DJ Newswires

Click to enlarge

This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.


Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.

Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
.